"Triflupromazine"@en . . . " "@en . "Triflupromazine"@en . . . "2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine"@en . . . . . "Triflupromazinum"@en . . . . . "Triflupromazine binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone (CTZ) and vomiting centre. Triflupromazine blocks the neurotransmitter dopamine and the vagus nerve in the gastrointestinal tract. Triflupromazine also binds the muscarinic acetylcholine receptors (M1 and M2) and the tryptamine D receptors (5HT_2B)."@en . . . . . "Fluopromazine"@en . "Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness."@en . "Humans and other mammals"@en . . "Triflupromazina"@en . "146-54-3"@en . "Used mainly in the management of psychoses. Also used to control nausea and vomiting."@en . . "Triflupromazin"@en . "A phenothiazine used as an antipsychotic agent and as an antiemetic. [PubChem]"@en . . . " "@en . "approved"@en . "Very high (90% or more)."@en . "Absorption may be erratic and peak plasma concentrations show large interindividual differences."@en . "10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine"@en . . . . . . "2-(Trifluoromethyl)promazine"@en . . . . . . . . . . . . . . . . .